Valuations of EQ-5D health states: are the United States and United Kingdom different?
about
Health state preferences are equivalent in the United States and Trinidad and TobagoThe impact of Medicare Part D on out-of-pocket costs for prescription drugs, medication utilization, health resource utilization, and preference-based health utilityEstimating a minimal clinically important difference for the EuroQol 5-Dimension health status index in persons with multiple sclerosis.Comparison of 3-Month Stroke Disability and Quality of Life across Modified Rankin Scale Categories.Health-related quality of life and health preference of Chinese patients with diabetes mellitus managed in primary care and secondary care setting: decrements associated with individual complication and number of complicationsEconomic evaluation and transferability of physical activity programmes in primary prevention: a systematic review.The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study.Percutaneous treatment of peripheral vascular disease: the role of diabetes and inflammationComprehensive health assessment and five-yr follow-up of allogeneic islet transplant recipients.Canadian valuation of EQ-5D health states: preliminary value set and considerations for future valuation studies.Population health status of South Asian and African-Caribbean communities in the United KingdomCost-effectiveness of fluocinolone acetonide implant versus systemic therapy for noninfectious intermediate, posterior, and panuveitis.Healthy eating and active living for diabetes in primary care networks (HEALD-PCN): rationale, design, and evaluation of a pragmatic controlled trial for adults with type 2 diabetesControlled trial of a collaborative primary care team model for patients with diabetes and depression: rationale and design for a comprehensive evaluation.Measuring preferences for cost-utility analysis: how choice of method may influence decision-makingDo chronic disease patients value generic health states differently from individuals with no chronic disease? A case of a multicultural Asian population.Utility values associated with diabetic retinopathy in Chennai, India.Decomposing cross-country differences in quality adjusted life expectancy: the impact of value sets.Assessing responsiveness of generic and specific health related quality of life measures in heart failureMaternal health-related quality of life after induction of labor or expectant monitoring in pregnancy complicated by intrauterine growth retardation beyond 36 weeksA critical re-evaluation of the regression model specification in the US D1 EQ-5D value functionEvaluating the discriminatory power of EQ-5D, HUI2 and HUI3 in a US general population survey using Shannon's indicesMultivariate Meta-Analysis of Preference-Based Quality of Life Values in Coronary Heart Disease.Utilities of Patients with Hypertension in Northern Vietnam.Health utility scores for people with type 2 diabetes in U.S. managed care health plans: results from Translating Research Into Action for Diabetes (TRIAD)Valuing health in a racially and ethnically diverse community sample: an analysis using the valuation metrics of money and timeImpact of anxiety symptoms on outcomes of depression: an observational study in Asian patients.Comparing Utility Scores in Common Spinal Radiculopathies: Results of a Prospective Valuation Study.A comparison of EQ-5D index scores using the UK, US, and Japan preference weights in a Thai sample with type 2 diabetes.Do concomitant pain symptoms in patients with major depression affect quality of life even when taking into account baseline depression severity?Radiofrequency volumetric thermal ablation of fibroids: a prospective, clinical analysis of two years' outcome from the Halt trial.Socioeconomic status and age variations in health-related quality of life: results from the national health measurement studyHome-based, peer-led chronic illness self-management training: findings from a 1-year randomized controlled trial.Mapping the EQ-5D index from the SF-12: US general population preferences in a nationally representative sample.Outcome instruments: rationale for their useHow Are We Measuring Patient Satisfaction After Anterior Cruciate Ligament Reconstruction?Swedish experience-based value sets for EQ-5D health states.Development and Validation of a Novel Generic Health-related Quality of Life Instrument With 20 Items (HINT-20).Comorbidity and disease burden in the National Comorbidity Survey Replication (NCS-R).Challenges to time trade-off utility assessment methods: when should you consider alternative approaches?
P2860
Q24609678-939049D9-3DBA-47CE-BB1B-1A9BE099A4DFQ28238484-A8AA852C-6C58-49E6-BE53-B2387FFD9ACDQ33598958-9F66952D-9F03-408F-91F3-756C871705B3Q33781992-6D0BA64D-B80D-4F33-9161-F6E0FF34EDD6Q33795712-E0601055-B747-41C5-8553-1A968F23714DQ33859085-043FC26A-B05A-48B1-9867-B42106BCE14DQ33923245-C8D4D9A5-C708-41F8-BA76-F63D13653548Q34018425-F41E4579-5075-4889-9AE3-31FF407D2E4FQ34045075-A060301F-BA25-45C4-9329-2D4E7673DC45Q34157292-982DDEFD-AF68-4A22-9544-67C5D4D86ADAQ34245475-6D97B5B4-80CB-4E35-AE13-1A03D8BCB249Q34258708-DFFBB6FB-01E2-4BE9-8A64-C89D9B58034CQ34309015-B221C062-65B8-434A-8754-D1DC881DC661Q34381700-846D7C0C-F2A7-4747-ACDE-3257445D9C34Q34614168-0A8A64EB-F945-4B35-921B-B6BDE72C0C18Q35030029-DBD6BA12-89E5-44AE-858C-360D3DFBD825Q35131740-72582F3B-304E-4CD0-AF1C-62A252B0A8DBQ35137275-7B0D627F-08C7-4BA6-B827-E2E8E74B0F16Q35185453-4E5F3A6E-5CE4-4799-9C1C-84F46BF22FA0Q35372982-B613E45C-C56D-4939-B18E-0355E5575C50Q35771943-8C79730C-909A-4E68-B970-11F0FC762E93Q35884227-91024ED5-64B2-4535-B4A1-4CFB8CF461AFQ35969302-A99438E6-A068-4988-A68C-73EA8C4BFBE7Q36218028-0E8E03B1-A2C2-470E-A073-620C384D679AQ36334618-41817000-826C-4B2C-830D-E9F653FCDD12Q36682279-29039F74-D33D-493E-808C-9B77435BF65AQ36802781-1D002B70-2237-4CDA-A983-22BABBC639A2Q36813425-DC70B396-E111-4D67-BA46-5A617CF724E1Q36919790-C7E17692-DB7A-43F8-9335-12F1C16B8716Q36957237-75DBC127-85E4-4CC1-827C-6168F6B9CD8CQ37115192-2AD6B30C-F158-4F30-A510-9E11F7EF1124Q37161158-AFF4D2FA-9B1B-4463-87A7-38F4ADB65926Q37268216-C39B684C-832F-45E7-8A4B-A546A7B3EC2CQ37268243-16D00A4A-7F6E-41E9-AC6C-858E78702C8AQ37468012-3C5E05F4-E2B3-4751-9378-15A3C592885CQ37632302-9FCD1A8B-38D0-4E9F-8A83-976EBD3EED5BQ37666482-4BFFEF72-C747-45E2-B57D-ED722CC8C10BQ37668663-FD12709C-D6ED-44F3-9A67-D83B4D3E83E8Q37734287-E8C0AEAA-0A1C-4E92-9222-20123E0D7B92Q38212030-F007A756-1D55-4CCB-94F0-334CD8602BF0
P2860
Valuations of EQ-5D health states: are the United States and United Kingdom different?
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Valuations of EQ-5D health states: are the United States and United Kingdom different?
@en
Valuations of EQ-5D health states: are the United States and United Kingdom different?
@nl
type
label
Valuations of EQ-5D health states: are the United States and United Kingdom different?
@en
Valuations of EQ-5D health states: are the United States and United Kingdom different?
@nl
prefLabel
Valuations of EQ-5D health states: are the United States and United Kingdom different?
@en
Valuations of EQ-5D health states: are the United States and United Kingdom different?
@nl
P2093
P1433
P1476
Valuations of EQ-5D health states: are the United States and United Kingdom different?
@en
P2093
James W Shaw
Stephen Joel Coons
P304
P356
10.1097/00005650-200503000-00004
P577
2005-03-01T00:00:00Z